Curis LifesciencesNSE:CURIS 31 Gross Margin % is 30.33% as of Mar. 2026, which is 5% below its 10-year median of 31.83. GuruFocus rates NSE:CURIS with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 943 Drug Manufacturers companies, Curis Lifesciences ranks worse than 80.28% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Curis Lifesciences had a gross margin of 30.33% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Curis Lifesciences Gross Margin % Related Terms
Curis Lifesciences Gross Margin % Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences Gross Margin % Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Gross Margin %
20.22
35.07
33.33
30.33
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
Gross Margin %
20.22
35.07
33.33
30.33
NSE:CURIS vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Curis Lifesciences (NSE:CURIS) has a Gross Margin % of 30.33% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Curis Lifesciences and its competitors. This is near median its historical median of 31.83. Over the past decade, Curis Lifesciences' Gross Margin % has ranged from 20.22 to 35.07. According to the industry distribution chart, Curis Lifesciences ranks #757 out of 943 companies in the Drug Manufacturers industry, placing it in the top 80.3%.
Is Curis Lifesciences' Gross Margin % too high?
Curis Lifesciences' current Gross Margin % of 30.33% is near median its 10-year median of 31.83. Over the past 10 years, this metric has ranged from a low of 20.22 to a high of 35.07. The Drug Manufacturers industry median Gross Margin % is 48.54. Curis Lifesciences' value of 30.33% is 37.5% below this industry median. Based on the distribution chart, Curis Lifesciences ranks #757 out of 943 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Curis Lifesciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #757 out of 943 companies for Gross Margin %. This places Curis Lifesciences in the lower half of its industry. The industry median Gross Margin % is 48.54. Curis Lifesciences' value of 30.33% is 37.5% below this benchmark. Historically, Curis Lifesciences' own Gross Margin % has ranged from 20.22 to 35.07 over the past decade. While the company's 10-year median is 31.83 vs. the industry median of 48.54, Curis Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current Gross Margin % of 30.33% is 37.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current Gross Margin % is 30.33%, which is near median its own 10-year median of 31.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current Gross Margin % of 30.33%. The current Gross Margin % is 30.33%, which is near median its 10-year median of 31.83 and 37.5% below the Drug Manufacturers industry median of 48.54. Curis Lifesciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current Gross Margin % is 30.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
31GF Score
Get the complete analysis for NSE:CURIS
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 